相关参考文献
注意：仅列出部分参考文献，下载原文获取全部文献信息。The addition of bendamustine to brentuximab vedotin leads to improved rates of complete metabolic remission in children, adolescents and young adults with relapsed and refractory classical Hodgkin lymphoma: a retrospective single-centre series
Annabel McMillan et al.
BRITISH JOURNAL OF HAEMATOLOGY (2021)
Combination brentuximab vedotin and bendamustine for pediatric patients with relapsed/refractory Hodgkin lymphoma
Christopher J. Forlenza et al.
BLOOD ADVANCES (2021)
Effectiveness of brentuximab vedotin monotherapy in relapsed or refractory Hodgkin lymphoma: a systematic review and meta-analysis
Wouter J. Plattel et al.
LEUKEMIA & LYMPHOMA (2021)
Brentuximab vedotin monotherapy is an effective treatment in a frail pediatric patient with Down syndrome and classical Hodgkin lymphoma
Julia Vonasek et al.
PEDIATRIC BLOOD & CANCER (2020)
Comparison of Hodgkin's Lymphoma in Children and Adolescents. A Twenty Year Experience with MH'96 and LH2004 AIEOP (Italian Association of Pediatric Hematology and Oncology) Protocols
Roberta Burnelli et al.
CANCERS (2020)
Safety and Efficacy of Brentuximab Vedotin in the Treatment of Classic Hodgkin Lymphoma
Shinichi Makita et al.
ONCOTARGETS AND THERAPY (2020)
Risk and Response Adapted Treatment Guidelines for Managing First Relapsed and Refractory Classical Hodgkin Lymphoma in Children and Young People. Recommendations from the EuroNet Pediatric Hodgkin Lymphoma Group
Stephen Daw et al.
HEMASPHERE (2020)
ESCMID Study Group for Infections in Compromised Hosts (ESGICH) Consensus Document on the safety of targeted and biological therapies: an infectious diseases perspective (Agents targeting lymphoid or myeloid cells surface antigens [II]: CD22, CD30, CD33, CD38, CD40, SLAMF-7 and CCR4)
L. Drgona et al.
CLINICAL MICROBIOLOGY AND INFECTION (2018)
Brentuximab Vedotin with Chemotherapy for Stage III or IV Hodgkin's Lymphoma
J. M. Connors et al.
NEW ENGLAND JOURNAL OF MEDICINE (2018)
Pulmonary toxicity in paediatric patients with relapsed or refractory Hodgkin lymphoma receiving brentuximab vedotin
Kelly E. Faulk et al.
BRITISH JOURNAL OF HAEMATOLOGY (2018)
Brentuximab vedotin with gemcitabine for paediatric and young adult patients with relapsed or refractory Hodgkin's lymphoma (AHOD1221): a Children's Oncology Group, multicentre single-arm, phase 1-2 trial
Peter D. Cole et al.
LANCET ONCOLOGY (2018)
Population Pharmacokinetics of Brentuximab Vedotin in Patients With CD30-Expressing Hematologic Malignancies
Hong Li et al.
JOURNAL OF CLINICAL PHARMACOLOGY (2017)
Pediatric Hodgkin Lymphoma
Christine Mauz-Koerholz et al.
JOURNAL OF CLINICAL ONCOLOGY (2015)
Recommendations for Initial Evaluation, Staging, and Response Assessment of Hodgkin and Non-Hodgkin Lymphoma: The Lugano Classification
Bruce D. Cheson et al.
JOURNAL OF CLINICAL ONCOLOGY (2014)
HSV-1 cutaneous infection in a patient with Hodgkin's lymphoma treated with brentuximab vedotin
Matteo Bassetti et al.
JOURNAL OF CHEMOTHERAPY (2013)
Safety and efficacy of brentuximab vedotin for Hodgkin lymphoma recurring after allogeneic stem cell transplantation
Ajay K. Gopal et al.
BLOOD (2012)
Results of a Pivotal Phase II Study of Brentuximab Vedotin for Patients With Relapsed or Refractory Hodgkin's Lymphoma
Anas Younes et al.
JOURNAL OF CLINICAL ONCOLOGY (2012)
Brentuximab Vedotin (SGN-35) for Relapsed CD30-Positive Lymphomas.
Anas Younes et al.
NEW ENGLAND JOURNAL OF MEDICINE (2010)
Differences in hematotoxicity between male and female patients with Hodgkin lymphoma and other malignancies
Beate Klimm et al.
NATURE CLINICAL PRACTICE ONCOLOGY (2008)
Long-term results of autologous stem cell transplantation for primary refractory or relapsed Hodgkin's lymphoma
Navneet S. Majhail et al.
BIOLOGY OF BLOOD AND MARROW TRANSPLANTATION (2006)
cAC10-vcMMAE, an anti-CD30-monomethyl auristatin E conjugate with potent and selective antitumor activity
JA Francisco et al.
BLOOD (2003)
分享论文
